SynthesisFrontiers in oncology2026
Efficacy of UFT combined with radiotherapy in advanced pancreatic cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tegafur-uracil (UFT) combined with radiotherapy is a treatment option for advanced pancreatic cancer. The purpose of this study was to evaluate the overall efficacy and safety of this combination therapy and explore potential factors associated with treatment outcomes. Method: The meta-analysis was in line with the PRISMA 2020 and MOOSE guidelines. Web of Science, PubMed, Scopus and Embase databases were searched for eligible studies. The outcomes variables were objective response rate (ORR) and adverse drug reaction (ADR). Pooled proportions were synthesized using meta-analysis method with a random-effect model. Influential publication was determined by performing a sensitivity analysis. In addition, the potential sources of heterogeneity were examined using subgroup analyses. Publication bias was assessed using a funnel plot, Begg's and Egger's tests. Results: The 7 observational studies, included for the SRMA, were conducted between 2004 and 2016, involving secondary data of 237 patients who underwent UFT combined with radiotherapy. We found that the pooled ORR of UFT combined with radiotherapy was 38% (95% CI: 13% to 67%, Conclusion: UFT combined with radiotherapy is an effective and tolerable treatment strategy for patients with advanced pancreatic cancer, with a pooled ORR of 38% and an ADR of 21%. Age of the patients and drug dosage were significant determinants of treatment outcomes. However, further research is needed to confirm these findings in large-scale randomized controlled trials. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261377332, identifier, CRD420261377332.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.